09:54 AM EST - Acerus Pharmaceuticals Corporation : Has filed a New Drug Submission for Avanafil with Health Canada. Avanafil, a treatment for erectile dysfunction, is a new, second generation PDE5 inhibitor, which has increased receptor specificity for fast onset of action and lower off-target side effects. Acerus Pharmaceuticals Corporation
shares T.ASP are trading up $0.005 at $0.13.
